Skip to main content
. 2018 Jan 22;293(10):3747–3757. doi: 10.1074/jbc.M117.818377

Figure 5.

Figure 5.

Human PXR activation in hMDMs leads to drug nonresponsiveness. A, intracellular survival assay of M. tuberculosis H37Rv, exposed to an incremental concentration of rifampicin (0.025 to 1 μg/ml) in the presence and absence of ketoconazole in control and PXR overexpressing hMDMs. B, CYP3A4-XREM promoter reporter assay in COS1 cells overexpressing hPXR treated with different concentrations of rifampicin (0.025 to 1 μg/ml) in the presence or absence of ketoconazole. C and D, intracellular survival of rifampicin-sensitive (C) and rifampicin-resistant (D) M. tuberculosis as monitored by CFU assay in control, PXR knockdown, and PXR overexpressing hMDMs in the presence or absence of 0.25 μg/ml of rifampicin for 48 h. Data are mean ± S.D. from three independent experiments each performed in triplicate. *, p < 0.05 compared with control or as indicated.